The FDA accepted Biogen’s Alzheimer’s drug submission. Next up, a highly anticipated outside expert review
The Food and Drug Administration has agreed to review a marketing application submitted by Biogen for aducanumab, its treatment for Alzheimer’s disease, the company announced Friday.
The aducanumab application was granted priority review, which means the FDA will render an approval decision no later than March 7, 2021.
